Gefitinib Unknown Status Phase 2 / 3 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

Unknown StatusTreatment2 / 3 IdentifierTitleDrugs
NCT01746277Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
NCT01784549Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
NCT02319577GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
NCT01755923Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
NCT01510990First Line Gefitinib by FDG-PET Metabolic Response
NCT00319800Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
NCT01833572Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
NCT01312337Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)